dabigatran vs sofosbuvir/velpatasvir
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of dabigatran and sofosbuvir/velpatasvir. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
Anticoagulants: dabigatran etexilate ↑ dabigatran Clinical monitoring of dabigatran is recommended when coadministered with VOSEVI. Refer to dabigatran etexilate prescribing information for dose modification recommendations in the setting of moderate renal impairment.
Pradaxa
Epclusa
Dabigatran (Pradaxa) is a drug that helps to prevent blood clots from forming. It is used to lower the risk of stroke and treat or prevent other dangerous clots in your body.
Vosevi is a drug that combines three medicines into one tablet. It is used to treat hepatitis C in adults who have already tried other treatments.
This medicine can help prevent strokes in people with an irregular heartbeat called atrial fibrillation. It can also treat blood clots in your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE). Dabigatran can also lower the risk of these clots coming back. It is also used to prevent blood clots after hip replacement surgery.
Vosevi treats chronic hepatitis C (HCV) infection in adults. It is for those without cirrhosis or with compensated cirrhosis (Child-Pugh A). You can use it if you have genotype 1, 2, 3, 4, 5, or 6 HCV. You must have already been treated with a hepatitis C medicine containing an NS5A inhibitor, or sofosbuvir without an NS5A inhibitor (for genotypes 1a or 3).
Dabigatran is a direct thrombin inhibitor. Thrombin is a substance in the blood that helps clots form. By blocking thrombin, dabigatran helps to keep your blood from clotting too easily.
Vosevi contains sofosbuvir, velpatasvir, and voxilaprevir. Sofosbuvir blocks a protein called NS5B polymerase that the hepatitis C virus needs to multiply. Velpatasvir blocks the NS5A protein, and voxilaprevir blocks the NS3/4A protease protein, both of which the virus also needs.
- • Upset stomach
- • Bleeding more easily (such as nosebleeds or heavier periods)
- • Headache
- • Fatigue (feeling tired)
- • Diarrhea
- • Nausea (feeling sick to your stomach)
No adverse event reports.
- Feeling tired 2,307
- Hepatitis C infection 1,734
- Headache 1,639
- Feeling sick to your stomach 1,386
- Low red blood cell count 1,185
Dabigatran has two important warnings. First, stopping this medicine too early can raise your risk of blood clots. Do not stop taking it without talking to your doctor. Second, this medicine can cause bleeding around the spine if you get an epidural or spinal tap. This can lead to paralysis. Tell your doctor if you are going to have any spinal procedures.
Vosevi can cause Hepatitis B to become active again if you have had it in the past. This can cause serious liver problems, including liver failure and death. Before starting Vosevi, your doctor will test you for Hepatitis B. They will also monitor you during and after treatment.
Talk to your doctor if you are pregnant or plan to become pregnant. Dabigatran may increase the risk of bleeding in the fetus. Breastfeeding is not recommended while taking this medicine.
It is not known if Vosevi can harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if Vosevi passes into breast milk, so discuss this with your doctor if you are breastfeeding.
How to Read This dabigatran vs sofosbuvir/velpatasvir Comparison
dabigatran is classified in the Direct Thrombin Inhibitor drug class, while sofosbuvir/velpatasvir sits within the NS5B/NS5A Inhibitor (HCV) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, dabigatran has 0 submissions while sofosbuvir/velpatasvir has 8,251. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to this combination can raise the amount of dabigatran in your blood.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for dabigatran or sofosbuvir/velpatasvir.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.